Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 23, 2005

View Archived Issues

Pharmexa files to start second phase II HER-2 Protein AutoVac study

NLA Nasal Spray shows rapid relief after histamine challenge

Schering-Plough completes acquisition of most NeoGenesis assets

VIGIV approved to treat complications of smallpox vaccination

Novartis to acquire generics players Hexal and Eon Labs

Henry Ford Hospital studies Viagra for stroke recovery

Spectrum acquires exclusive license to endothelin B agonists for cancer

Ammonul approved for urea cycle disorder

Biosite launches Triage D-Dimer Test

Triage Stroke Panel PMA accepted for review

Bavarian Nordic invests in smallpox vaccine production, product development

Excellent pharmacokinetic profile of antitubercular drug SQ-109

Rasagiline treatment benefits levodopa-treated Parkinson's disease patients

XP-828L reported to improve the symptoms of chronic plaque psoriasis

IDEA-070 reported better than hydrocortisone-21-acetate in UV-induced sunburn

Tamoxifen reduces myocardial infarction, angina

Update on bevacizumab in colorectal cancer

Prialt approved in Europe

Approvable letter for Surfaxin

European approval for Azilect

Prostaglandin D2 (DP) receptor antagonists disclosed by Merck Frosst

Glenmark presents novel PDE4 inhibitors for inflammatory and allergic conditions

The use of novel beta-secretase inhibitors for Alzheimer's disease claimed by GSK

Hadasit researchers disclose a uPA-derived octapeptide for the treatment of MS

AEgera discovers new agents for the treatment of cancer and neuronal disorders

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 8, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 8, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...